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Introduction
Glial cells are present in the brain and spine, as they 
surround neurons and support them. Any uncontrollable 
and excessive growth in glial cells can lead to an 
aggressive form of brain cancer called glioma (Stupp 
et al., 2009; Stupp and Roila, 2009; Haar et al., 2012). 
Radiotherapy, chemotherapy and surgery are the currently 
used treatment option for people with glioma. However, 
cellular immunotherapy is a novel proven treatment which 
has raised hopes for therapy of several cancers (Yajima et 
al., 2005; Platten et al., 2016). In cancer immunotherapy, 
dendritic cells (DCs) and peptides are used for inducing 
anti-glioma responses which are capable of harnessing 
the power and specificity of the immune system to treat 
tumors (Liau et al., 2005). DCs are the most potent 
antigen-presenting cells of the body sensitizing T cells 
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toward all acquired antigens and tumor derived peptides. 
DCs present tumor-derived peptides to native CD8+ 
T cells and then these T cells can initiate a cytotoxic 
T lymphocyte (CTL) differentiation programme after 
countering DCs (Li et al., 2016). To activate the immune 
system in cancer immunotherapy, DCs are loaded with 
tumor derived peptides ex vivo, which can subsequently 
activate the endogenous immune system upon injection 
(Radford et al., 2014). There are several mice models 
of cancer reports proving that DCs can capture tumor 
antigens of tumor cells and cross-present these antigens 
to T cells in tumor-draining lymph nodes that leads to the 
generation of tumor specific CTLs and contribute to tumor 
rejection (Richters et al., 2002; Pellegatta et al., 2006). 
Thus, DCs represent themselves as an important target 
for therapeutic interventions in cancer therapy and can 
be generated in vitro from monocytes by using GM-CSF 
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and IL-4, and are therefore, called monocyte-derived DC 
(MoDC) (Tuyaerts et al., 2007; Guo et al., 2016).
Heat shock proteins-peptide complexes (HSP-PC) 
from tumors have proven to be extremely effective in 
inducing antitumor immunity. This is because lysates 
from heat-stressed tumor cells prepare an optimal 
source of tumor antigens to generate DC with mediated 
cross-presentation and thus can be used in clinical orders 
for DC cell-based vaccination against tumors (Schnurr 
et al., 2001; Nakai et al., 2006; Aguilera et al., 2011). 
Moreover, it has been reported that in large numbers of 
glial cells, heat stress up to 43˚C for 90 min could induce 
HSP72 expression (Satoh and Kim, 1994).
Tumors are complicated tissues and contain multiple 
types of cells such as mesenchymal, immune, and vascular 
endothelial cells. Accordingly, extensive studies have been 
carried out to explain the interaction between cancer cells 
and their microenvironment. Multipotent mesenchymal 
stromal cells (formerly known as MSC) are increasingly 
used in cell-based therapies (Murphy et al., 2016). They 
are simply separated from other bone marrow-derived 
cells by their tendency to adhere to plastic (Nakamizo 
et al., 2005; Vu et al., 2016). Upon residing in the tumor 
microenvironment, MSCs targeted cancers are expected to 
release many bioactive factors, like mitogens, extracellular 
matrix proteins, angiogenic and inflammatory factors, as 
well as exosomes or MVs (Waterman et al., 2012; Senst et 
al., 2013). MSCs appear to affect the immune system by 
changing the proliferation and differentiation of dendritic 
cells, monocytes, macrophages, B and T cells, NK cells, 
including mast cells (Klopp et al., 2010; Klopp et al., 
2011; Waterman et al., 2012). Evidence from several 
studies, have shown that MSCs can recruit and regulate 
T cells in both cell to cell contact and paracrine signaling 
(Beyth et al., 2005; Wang et al., 2014). However, there 
is a growing concern over the use of MSCs because they 
host tumors and can sustain tumor growth and metastasis. 
Nonetheless, recent studies defined a new approach for 
the polarization of MSCs in to a pro-inflammatory MSC1 
and an immunosuppressive MSC2 phenotype (Waterman 
et al., 2010; Klopp et al., 2011). This is explained as the 
stimulation of TLR4 (Toll Like Receptor 4) in MSCs with 
lipopolysaccharides (LPS) resulting in MSC1 phenotype 
which has an anti-tumor effect and decrease tumor growth 
and metastasis (Waterman et al., 2012). 
Experimental studies have detected that the useful 
effects of MSCs is relatively indirect and rely on the 
paracrine activity of MSCs and not on their engraftment. 
Therefore, at the core of the development of cell free 
strategies are novel therapeutic visions based on the 
application of MSCs-derived MVs as a safe and more 
beneficial alternative to cell therapy approaches (Collino 
et al., 2010; Bruno et al., 2012). These cell-derived MVs 
include survival signals such as growth factors and 
cytokines, therefore, providing promising results that 
indicate MSC-derived MVs have the same protective and 
supportive features as their original cells in tissue repair 
and anticancer therapy (Parekkadan et al., 2007). Unlike 
MSCs, MVs have some properties that that present them 
as stable, long lasting effectors with no risk of immune 
rejection (Lai et al., 2010), generate severe signals 
(Farsad, 2002), and their functions do not exhaust over 
time (Uccelli et al., 2008). However, the consequence of 
MSCs-derived MVs have not yet been studied in T cells 
mediated responses in the field of cancer therapy. 
Therefore, in this study, we utilized MSC1-derived 
MVs as a pro-inflammatory cell free vesicle to form a 
viable basis for the development of novel cancer vaccines, 
via antigen-presenting cell technology. Furthermore, the 
study addresses the potential application of MSC1-derived 
MVs as a novel nanoscale immunotherapy treatment for 
cancer, by stimulating effective antitumor T-cell immunity.
Materials and Methods
Primary cell culture 
B92 rat glial cell line was purchased from National Cell 
Bank of Iran (NCBI, Tehran, Iran) and was sub-cultured in 
RPMI 1640 supplemented with 10% FBS at an atmosphere 
of 5% CO2 and 37 oC to reach 80% confluency.
Heat stress
We used heat stressed tumor lysates as a source of 
tumor-associated antigens for pulsing DCs. Heat treatment 
was applied according to the method described before 
(Satoh and Kim, 1994). In brief, culture flasks were closed 
and immersed at 43 oC water bath for 90 min, subsequently 
incubated for 8 h at 37°C and 5% CO2. The viability of 
the heat stressed cells was more than 95%.
Preparation of tumor lysates 
To obtain tumor lysates 3 × 106 B92 cells were 
trypsinized and washed in medium twice and then 
followed by four freezes (liquid nitrogen) and thaw 
(37 oC water bath) cycles. Large particles were removed 
by centrifugation (2,000 g for 10 min, followed by 13,000 
g for 60 min at 4 oC) then lysate was filtered through a 
0.22 μm mesh. The protein content was determined by the 
Coomassie blue protein assay (Biorad, London, UK) and 
aliquots were stored at – 80 oC. These steps were done 
according to previous methods (Aguilera et al., 2011).
Isolation, proliferation and identification of MSCs
MSCs were isolated as explained previously with 
some modifications (Mokarizadeh et al., 2012). Briefly, 
bone marrow was flush out of tibias and femurs 
from deeply anesthetized Wistar rats. The cells were 
suspended and centrifuge at 2,00 g, 4°C for 5 min then 
plated in flasks using low-glucose Dulbecco’s Modified 
Eagle’s Medium containing 15% FBS and incubated in 
humidified 5% CO2 at 37 °C. Three days after primary 
culture, the culture medium (CM) was collected and 
centrifuged, then the pellets were replated in a fresh 
flask. The cultures were changed with fresh ones twice a 
week and after reaching 70% confluence, the cells were 
removed using Trypsin-EDTA, counted, and passed at T75 
flask. Cells of third passage were used to TLR priming. 
The immunophenotype of 3rd passage of MSCs were 
analyzed by flow cytometry using DAKO flow cytometry 
(Partec, Germany) as described before. The fallowing 
monoclonal Antibodies were used: FITC- labeled 
anti-CD45, PE-labeled anti-CD29 and PCY5-labeled 
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T cell cytotoxicity assay 
Tumor antigen primed T cells were co-cultured with 
B92 tumor cells in 96-well V-bottom plates at an effector: 
target ratio of 100:1 (T cells: B92) in a final volume of 
200 μl at 37°C and incubated for 3 h. The incubation was 
done in shaking incubator to prevent the adherent of B92 
tumor cells. After co-incubation, cells were harvested 
and washed with PBS and re-suspended in 200 µl ABB 
(Annexin Binding Buffer). Then were stained in 5 μg/ml 
annexin-FITC for 20 min at room temperature in the dark 
and immediately before flow cytometric analysis, 5 μg/
ml propidium iodide (PI) was added. Three color FACS 
analysis was carried out on a Coulter cytometer (Partec 
Germany). Unstained and annexin-FITC/PI stained B92 
cells were used as respective controls. Duplicate wells 
were averaged and the percentage of specific lysis was 
calculated as fallow:
Specific Lysis= (sample-control)/ (total-control) ×100
In this formula control and total indicate target cells.
Ethics Statement
This study was conducted with permission from 
the Animal Ethics Committee of Ardabil University 
of Medical Sciences (Ethical code: IR.ARUMS.
REC.1394.133). The animal procedures followed in this 
study were in accordance with the standards set forth in 
the Guide for the Care and Use of Laboratory Animals.
Statistical analysis
Means of at least 3 independent experiments were 
reported. The data were analyzed by SPSS software One 
Way ANOVA and LSD test. The level of significance was 
set at p<0.05 and results were presented as mean ±SD.
Results
Morphological appearance of monocyte derived mature 
DCs
PBMCs were incubated for 2 h at 37 °C and adherent 
population were cultured in the presence of GM-CSF 
and IL-4 for three days. On day 4, immature DCs were 
pulsed with tumor antigen to obtain two test groups: 
non-heated stressed tumor lysate group (unheated ones) 
and heat stressed tumor lysate group. On day 5, LPS as a 
maturation factor was added and by day 7, 60% of cells 
appeared to loosely adhere to each other in clumps or were 
isolated floating cells with typical dendritic morphology. 
On day 7, mature DCs were harvested and reviewed 
using invert microscopy. At this stage, there were no 
significant differences between the unheated stressed 
tumor lysate and heat stressed tumor lysate or both DCs 
of the test groups that exhibited similar typical cytological 
features, i.e., large irregular cells with numerous cell 
membrane processes under light microscopy (Figure 
1). In our previous studies, immunophenotyping of 
monocyte-derived DCs and primed T cells was performed 
(Delirezh et al., 2009; GanjiBakhsh et al., 2011). 
Characterization and morphological appearance of MSCs
This study was carried out simultaneously with another 
anti-CD90 (Becton Dickinson). Isotype control were used 
in all cases. Moreover, the capabilities of the 3 passages of 
MSCs to differentiate in to osteocytes and adipocytes were 
examined as previously described (Abbasi et al., 2018). 
TLR priming
The 3rd passage of MSCs was cultured and upon 
60–70% confluence, LPS (10 ng/ml) (Sigma-Aldrich) was 
added to fresh CM as TLR4 agonist and incubated for 1 
h as describe before (Waterman et al., 2010). The cells 
were then washed twice in CM without the TLR-agonists 
and used in the next steps of experiments.
Isolation of MVs
MVs were isolated by various centrifuge and 
ultracentrifuge as explained previously (Thery et al., 
2006). Briefly, the collected supernatant of MSCs CM 
was centrifuged at 300 g for 10 min, 1,000 g for 20 
min and 10,000 g for 30 min respectively. The final 
supernatant was ultra-centrifuged at 100,000 g for 2 h in 
the ultracentrifuge (Beckman coulter optimaTMXL-100K 
ultracentrifuge). The MV pellet was washed in phosphate 
buffer saline (PBS) and again centrifuged at 100,000 g 
for 2 h. The resultant pellet was re-suspended in PBS and 
stored at – 80 oC.
Generation of DCs
Dendritic cells were generated as previously described 
with minor modifications (Agger et al., 2000). Rats were 
anaesthetized and 15 ml heparinized blood was obtained 
by heart puncture. Peripheral blood mononuclear cells 
(PBMCs) were isolated by density gradient centrifugation 
on ficoll/hypaque (Lymphoprep, Norway). PBMC were 
then plated into T25 flask and incubated for 2 h at 37 oC 
to remove the non-adherent cells. The adherent cells were 
cultured for 7 days in medium containing rat recombinant 
GM-CSF (Peprotech, USA) and IL-4 (Peprotech, USA) at 
a concentration of 50 ng/ml. Cytokine containing medium 
was renewed every 2 days. At day 4 of experiment heat 
stressed tumor lysate was added to MoDC at final protein 
concentration of 50 μg/mL and incubated overnight. 
To induce maturation of the MoDC, 20 μg/ml LPS 
(Sigma-Aldrich) was added as a maturation factor on day 
5. Mature DCs were harvested on day 7, and viability of 
cells was determined 95% as using trypan blue exclusion 
assay.
Cell priming
The rats were anaesthetized again and the same 
amount of heparinized blood was obtained by heart 
puncture. PBMCs were plated into T25 flask and 
incubated for 2 h and non-adherent cells were harvested 
to isolate the autologous T cells. 1 × 105 tumor lysate 
pulse MoDCs were cultured with 1 × 106 autologous T 
cells (ratio = 1:10) in CM supplemented with 10% FBS 
in the presence of 20 µg/ml MSC1-derived MVs in 24 
well microtiter plate for 7 days at 37 °C and 5% CO2. 
The culture was fed every 3 days with fresh medium and 
recombinant rat IL-2 (20 ng/ml) (Peprotech, USA). On 
day 7 tumor antigen primed T cells were harvested and 
applied to T cell cytotoxicity assay, respectively. 
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study and therefore, the cells which were characterized 
and described were used (Abbasi et al., 2018). MSCs 
were distinguished by their fibroblast like appearance, 
colony forming tendency, and their tendency to adhere 
plastic (Figure 2).
Electron microscopy analysis of microvesicles
Analyses of MVs by electron microscopy showed the 
presence of nano-sized vesicles. Size of majorities were 
between 50 to 200 nm in several micrographs (Figure 3).
Cell Cytotoxic Activity
We stimulated autologous T cells with antigen pulsed 
DCs to examine the capacity of heat stressed tumor lysate 
pulsed DC and MSC1-derived MVs to elicit cytotoxic T 
cell response in vitro. Subsequently the cytotoxic activity 
of primed T cells was analyzed using flow cytometry. 
Cytotoxicity assays were conducted with primed 
T cells at 7 days after stimulation of T cell with tumor 
lysate pulsed DCs in the presence of polarized MVs or 
MSC1-derived MVs and non-polarized MSC-derived 
MVs. cytotoxicity against tumor cells is shown in figures 
Figure 1. Monocyte- Derived Tumor Lysate Pulsed Dendrite Cells in 7 Days. Adherent population in the first day(A), 
immature DCs before pulsing with tumor lysate on day 4(B), immature DCs pulsed with tumor lysate on day 5(C), 
immature DCs pulsed with heat stressed tumor lysate on day 5(D), mature DCs pulsed with tumor lysate & LPS on 
day 7(E), mature DCs pulsed with heat stressed tumor lysate & LPS on day 7(F), all samples were reviewed by invert 
microscopy (400×).
Figure 2. Culture of MSCs on Days 1-14 and 3rd Passages. Pooled bone marrow-derived cells (A), bone marrow-
derived adherent cells on day 1(B), adherent cells on day 2(C), cells were becoming spindle-like on day 4 (D), a 
representative colony formed by MSCs on day 6 (E), high confluency at clonal density on day 8 (F), on day 10 (E), 
on day 12 (H) and on day 14 (I) after 3rd passages
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4 and 5 for 6 different groups at an effector: target (T cell: 
B92) ratio of 100:1 as follows: Treatment 1: glial tumor 
cells co-cultured with autologous T cells stimulated with 
tumor lysate pulsed DCs. Treatment 2: glial tumor cells 
co-cultured with autologous T cells stimulated with tumor 
lysate pulsed DCs in the presence of non-polarized MVs. 
Figure 3. Structural Analysis of MVs Derived from Bone 
Marrow-Derived Mesenchymal Stem Cells. MVs were 
isolated from CM of MSCs by differential centrifugation 
and observed by a transmission electron microscope 
(Philips Bio Twin, CM100, Netherlands) at 80 kV. MVs 
were seen as nano-sized vesicles in electron micrograph.
Figure 4. Flow Cytometric Analysis of the Cytotoxic 
Activity of Autologous T Cells Stimulated with Heat 
Stressed Tumor Lysate pulsed DCs in the Presence 
of MSC-derived MVs. this causes more death in the 
targeted tumor cells in comparison with the unheated 
ones (P≥ 0.05).
Figure 5. Early and Late Apoptosis as Well as Necrosis in Target Cells (B92 Tumor Cells) Induced by Tumor Lysate 
Pulsed DC Primed Cytotoxic T Lymphocytes in the Presence of MSC-Derived MVs (P≥ 0.05). The T cell mediated 
cytotoxicity assay was done using flow cytometry and data were analyzed by one-way-ANOVA.
Figure 6. Specific Lysis of Tumor Cells Induced by Tumor Lysate Pulsed DC Primed Cytotoxic T Lymphocytes in the 
Presence of MSC-Derived MVs (P≥ 0.05). The flow cytometry by annexin-FITC/ PI for stained and unstained B92 
tumor cells was used to determine specific lysis.
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Treatment 3: glial tumor cells co-cultured with autologous 
T cells stimulated with tumor lysate pulsed DCs in the 
presence of polarized MVs. Treatment 4: glial tumor cells 
co-cultured with autologous T cells stimulated with heat 
stressed tumor lysate pulsed DCs. Treatment 5: glial tumor 
cells co-cultured with autologous T cells stimulated with 
heat stressed tumor lysate pulsed DCs in the presence 
of non-polarized MVs. Treatment 6: glial tumor cells 
co-cultured with autologous T cells stimulated with 
heat stressed tumor lysate pulsed DCs in the presence of 
polarized MVs.
The results showed that heat stressed tumor lysate 
pulsed DC primed T cells, produced more cytotoxic activity 
than normal tumor lysate pulsed DCs non-significantly (P≥ 
0.05). Moreover, polarized MSC-derived MVs induced 
higher cytotoxic activity than non-polarized MSC-derived 
MVs non-significantly as well as (P≥ 0.05) (Figures 4 
and 6). Apoptosis and necrosis analyses also showed the 
aforementioned pattern of responses (Figure 5).
Discussion 
Cellular immunotherapy is currently being considered 
as a potential new treatment modality that may manipulate 
the immune system and perhaps in combination with 
other therapies raise hope for the survival of patients with 
glioma. Cancer immunotherapy primes the patient’s own 
immune system to raise effective antitumor responses 
against glial cancer cells. Recently, cancer vaccine studies 
have been based on autologous dendritic cells loaded 
with glial peptides or whole tumor lysates which can 
subsequently trigger the immune system upon injection 
(Sakai et al., 2015). DCs are the most effective antigen 
presenting cells for initiating cellular immune responses 
through the stimulation of naive T cells (Finocchiaro and 
Pellegatta, 2016). These DCs play a central role in various 
immunotherapy protocols as they induce CTLs. CD8+ and 
CD4+ T lymphocytes identify antigens in the context of 
MHC class I and class II molecules, respectively. MoDCs 
are a crucial reservoir of specialized antigen presenting 
cells that are recruited in immune responses to certain 
tumors (Saito et al., 2006). 
In the field of cancer therapy, the most notable 
properties of MSCs is their inherent ability to migrate 
towards tumor cells and provide many bioactive factors 
once resident (Sasportas et al., 2009). The migration of 
MSCs to tumors has been demonstrated in malignant 
glioma (Hai et al., 2012). It is remarkable that Waterman 
and his colleagues could separate MSCs from at least six 
different donors into two distinct phenotypes MSC1 and 
MSC2. MSC1 could reduce tumor growth and metastasis 
(Waterman et al., 2012). Various studies have shown that 
MSC-derived MVs possess equal features as their cellular 
counterparts in anti-cancer therapy (Sasportas et al., 2009). 
Some methods have been developed to produce DC 
in vitro from the bone marrow (Inaba et al., 1992) or 
peripheral blood monocytes (Sallusto and Lanzavecchia, 
1994). The method based on the use of MoDCs, seems to 
be the most practical strategy for clinical trials to induce 
antitumor responses. Hence, in the present study, MoDCs 
were loaded with tumor lysates in two forms; heated and 
unheated lysates and then matured in the presence of 
LPS. Previous studies (Adams et al., 2005; Bagheri et al., 
2008) as well as ours have described the matured DCs as 
non-adherent, large irregular veiled cells with numerous 
cell membrane processes. Morphological examination 
of floated cells using inverted microscopy at 7 days of 
culture revealed no obvious differences among these 
heated and unheated cell lysates loaded DCs (Figure 1). 
Therefore, we precede the work with the comparison of 
functional properties and the role of MSC1s-derived MVs 
on DC maturation and cytotoxicity of stimulated T cells 
afterwards.
In the current study we used heat stressed tumor 
lysate as tumor antigens. Our results showed that this 
kind of tumor cell lysate as HSP-PC may increases the 
tumor specific cytotoxicity of T cells non-significantly 
(P≥ 0.05). Lysates from heat-stressed tumor cells provide 
an optimal source of tumor antigens and generate DCs 
with improved cross-presentation potential (Aguilera et 
al., 2011). Chaperone-enriched tumor lysate seems to be 
more effective than purified HSP alone in inducing tumor 
specific responses in various murine models (Zeng et 
al., 2006; Prins et al., 2013). Therefore, chaperone-rich 
cell lysate vaccine elicits more immunological effect 
than any single chaperone proteins and is thus used 
independently as vaccines. Obviously, tumor lysate can 
mediate antigen cross-presentation and activate CD8+ 
T lymphocytes. However, the presentation of tumor 
antigens by DC is not sufficient for CTL programming 
in the absence of co-stimulatory molecules and innate 
immunity, since the “helpless” CD8+ cells will cease 
to proliferate abundantly and will most likely undergo 
apoptosis (Schurich et al., 2009; Kurts et al., 2010). One 
mechanism for enhancing CTL programming involves the 
activation of TLR pathways that result in the synthesis of 
co-stimulatory molecules (Rudd et al., 2009; Yamamoto 
and Takeda, 2010). Furthermore, tumor cells treated with 
elevated temperatures release inflammatory chemokines 
in an Hsp70 and TLR4 dependent mechanisms and this 
effect may be significant in CTL programming and tumor 
cell death (Chen et al., 2009). Flow cytometric annexin-
FITC/PI was used to the determination of apoptosis in 
B92 tumor cells. Previous studies of human MSCs have 
shown that co-culturing of MSC1 with cancer cells result 
in fewer tumor growth and much smaller angiogenesis in 
various cancer cell lines (Waterman et al., 2012). Also, 
MSC-derived MVs may reprogram tumor behavior 
by transferring their molecular contents and suppress 
angiogenesis by transferring anti-angiogenic molecules 
(Lee et al., 2013). Moreover, evidences suggest that MSCs 
are able to inhibit proliferation of K562 cells in a humoral 
microenvironment by secreting DKK-1 (dickkopf-1) 
(Zhu et al., 2009). In all, our studies on MSC/MSC1 
in co-culture showed that MSC1 derived MVs with 
heat stressed tumor lysate pulsed DCs may change the 
tumor specific cytotoxicity of T cells and may enhance 
T lymphocyte cytotoxicity against respective tumor cells 
non-significantly.
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